TaiAn Technologies
3
15M
3
0.14
- Areas of investment
Summary
In 2002 was created TaiAn Technologies, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Taipei. The venture was found in Asia in Taiwan.
The top activity for fund was in 2016. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Therapeutics, Biotechnology. Among the various public portfolio startups of the fund, we may underline Sapience Therapeutics, Sapience Therapeutics
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the TaiAn Technologies, startups are often financed by Healthlink Capital, Eshelman Ventures, Celgene. The meaningful sponsors for the fund in investment in the same round are Healthlink Capital, Eshelman Ventures, Celgene. In the next rounds fund is usually obtained by Michael J. Fox Foundation, Healthlink Capital, Eshelman Ventures.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Rounds per year
- 0.14
- Investments by industry
- Biotechnology (3)
- Therapeutics (2)
- Medical (2)
- Health Care (1)
- Health Diagnostics (1) Show 1 more
- Investments by region
-
- Taiwan (2)
- United States (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AnBogen Therapeutics | 31 Jan 2024 | Biotechnology, Medical | Early Stage Venture | 12M | Taitung County, Taiwan, Taiwan |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.